Methyprylon
Noludar (methyprylon) is a small molecule pharmaceutical. Methyprylon was first approved as Noludar on 1982-01-01. It is used to treat sleep initiation and maintenance disorders in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methyprylon
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOLUDAR | Roche | N-009660 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
181 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypogonadism | D007006 | E23.0 | 9 | 23 | 16 | 15 | 9 | 68 | |
| Eunuchism | D005058 | EFO_0007266 | E29.1 | 3 | 6 | 8 | 7 | 1 | 25 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | 4 | — | 5 |
| Healthy volunteers/patients | — | 3 | — | — | 1 | — | 4 | ||
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 2 | 1 | 1 | — | 4 |
| Wounds and injuries | D014947 | T14.8 | — | 3 | 1 | 1 | — | 4 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 3 | — | 1 | — | 4 |
| Klinefelter syndrome | D007713 | EFO_1001006 | Q98.0 | — | 1 | 1 | 2 | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | 2 | — | 3 |
| Psychological sexual dysfunctions | D020018 | F52.0 | 1 | — | 1 | 1 | — | 3 |
Show 15 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Transsexualism | D014189 | F64.0 | — | — | 2 | — | 2 | 4 | |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 4 | 1 | — | — | 4 | |
| Menopause | D008593 | EFO_0003922 | N95 | — | 3 | 1 | — | — | 4 |
| Muscular atrophy | D009133 | HP_0003202 | — | 2 | 2 | — | — | 3 | |
| Mobility limitation | D051346 | HP_0002355 | — | 1 | 1 | — | — | 2 | |
| Knee injuries | D007718 | — | 1 | 1 | — | — | 1 | ||
| Rotator cuff injuries | D000070636 | M75.1 | — | 1 | 1 | — | — | 1 | |
| Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | 1 | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 1 | — | — | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | 1 | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | 2 | 9 | — | — | 1 | 12 | |
| Castration-resistant prostatic neoplasms | D064129 | — | 6 | — | — | — | 6 | ||
| Pain | D010146 | EFO_0003843 | R52 | — | 3 | — | — | — | 3 |
| Androgen-insensitivity syndrome | D013734 | E34.5 | — | 2 | — | — | 1 | 3 | |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 1 | — | — | — | 2 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | 1 | — | — | 1 | 2 |
| Contraception | D003267 | 1 | 2 | — | — | — | 2 | ||
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 2 | — | — | — | 2 |
| Gonadal disorders | D006058 | — | 2 | — | — | — | 2 | ||
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 2 | — | — | — | 2 |
Show 23 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cachexia | D002100 | HP_0004326 | R64 | 2 | — | — | — | — | 2 |
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | — | — | — | — | 1 |
| Facioscapulohumeral muscular dystrophy | D020391 | EFO_0000491 | G71.02 | 1 | — | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | — | 1 |
| Priapism | D011317 | HP_0200023 | N48.3 | 1 | — | — | — | — | 1 |
| Squamous cell neoplasms | D018307 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Delayed puberty | D011628 | HP_0000823 | E30.0 | — | — | — | — | 2 | 2 |
| Duchenne muscular dystrophy | D020388 | — | — | — | — | 1 | 1 | ||
| Paraplegia | D010264 | HP_0001258 | G82.2 | — | — | — | — | 1 | 1 |
| Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 1 | 1 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METHYPRYLON |
| INN | methyprylon |
| Description | Methyprylon (Noludar) was a sedative of the piperidinedione derivative family developed by Hoffmann-La Roche.
This medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such as benzodiazepines.
Methyprylon was withdrawn from the US market in June 1975 and the Canadian market in September 1990.
Some other trade names are Noctan and Dimerin.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCC1(CC)C(=O)NCC(C)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 125-64-4 |
| RxCUI | 6910 |
| ChEMBL ID | CHEMBL1200790 |
| ChEBI ID | — |
| PubChem CID | 4162 |
| DrugBank | DB01107 |
| UNII ID | CUT48I42ON (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 155 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
128 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more